ansm
Agence nationale de sécurité du médicament et des produits de santé

Je soussigné Maître Yves TOUZET Notaire associé
à Lyon 6ème 139 rue Vendôme
CERTIFIE la présente copie conforme au document qui m'a été présenté comme un original.

19 JAN. 2017

Me Yves TOUZET, Notaire à LYON, COUR D'APPEL

1967

French National Agency for Medicines and Health Products Safety

CERTIFICATE NUMBER: ***16MPP088HFR01***

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER [1, 2]

Part 1

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:
The manufacturer: ***MERCK SANTE***
Site address: ***Zone Industrielle, 10 avenue du Maréchal de Lattre de Tassigny, MEYZIEU, 69330, France***

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2016-10-21*** , it is considered that it complies with :

- The principles of GMP for active substances [3] referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

---

[1] *The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.*

[2] *Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.*

[3] *These requirements fulfil the GMP recommendations of WHO.*

CONSULADO GENERAL DE CHILE
EN PARIS

EL CONSUL GENERAL DE CHILE QUE SUSCRIBE
CERTIFICA LA AUTENTICIDAD DE LA FIRMA DE DON
A HERPIN
FUNCIONARIO DEL MINIST. DE RR. EE. DE FRANCIA

AXEL CABRERA MARTINEZ
CÓNSUL GENERAL DE CHILE

REPUBLIQUE FRANÇAISE
LEGALISATION
(DECRET N°2007-1205 DU 10 AOUT 2007)
DESTINATION DE L'ACTE (PAYS OU AUTORITE)
DATE : 10 FEV. 2017
NOM ET QUALITE DE L'AGENT : A. HERPIN
BUREAU DES LEGALISATIONS
SIGNATURE
ET CACHET OBLIGATOIRE :
MINISTERE DES AFFAIRES ETRANGERES

SERVICIO CONSULAR 2017 10 US$ CHILE 10 US$

Actuacion N° ..... Arancel Articulo N° 440
Derechos US$ 12 Diferencia 10% 1,20
Total percibido en US$ 13,20
Pagado en moneda local 12 €
Paris 13 FEV. 2017

SERVICIO CONSULAR 2017 2 US$ CHILE 2 US$

boulevard Anatole France - F-93285 Saint-Denis Cedex - Tél.: +33(0)1 55 87 30 00 - www.ansm.sante.fr

Part 2

Manufacture of active substance. Names of substances subject to inspection :
NAFTIDROFURYL (HYDROGENOOXALATE DE)(fr) / NAFTIDROFURYL HYDROGEN OXALAT E(en)
NITROFURANTOINE MACROCRISTAUX(fr) / NITROFURANTOIN MACROCRISTAL(en)
ACAMPROSATE CALCIQUE(fr) / ACAMPROSATE CALCIUM(en)
DANTROLENE SODIQUE(fr) / DANTROLENE SODIUM(en)
FLUINDIONE(fr) / FLUINDIONE(en)
HYMECROMONE(fr) / HYMECROMONE(en)
METFORMINE (CHLORHYDRATE DE)(fr) / METFORMIN HYDROCHLORIDE(en)
METFORMIN HYDROCHLORIDE AND 0.5% MAGNESIUM STEARATE(en) / METFORMINE (CHLORHYDRATE DE) + 0.5 % DE STEARATE DE MAGNESIUM(fr)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : NAFTIDROFURYL HYDROGEN OXALATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying grinding mixing 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : NITROFURANTOIN MACROCRISTAL

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying sifting 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for

143/147 boulevard Anatole France - F-93285 Saint-Denis Cedex - Tél.: +33(0)1 55 87 30 00 - www.ansm.sante.fr

	identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : ACAMPROSATE CALCIUM

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying grinding 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : DANTROLENE SODIUM

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying grinding 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : FLUINDIONE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**

	3.5.1 Physical processing steps : Drying grinding 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : HYMECROMONE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying sifting 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : METFORMIN HYDROCHLORIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying mixing 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : METFORMIN HYDROCHLORIDE AND 0.5% MAGNESIUM STEARATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**

143/147 boulevard Anatole France - F-93285 Saint-Denis Cedex - Tél.: +33(0)1 55 87 30 00 - www.ansm.sante.fr

	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying mixing 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.5.4 Other : blending with magnesium stearate
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

2017-01-05

Name and signature of the authorised person of the Competent Authority of France

Le chef du pôle inspection des matières premières
Direction de l'inspection

Guillaume RENAUD

Mr. Guillaume Renaud
French National Agency for Medicines and Health Products Safety
Tel: *+33 1 55873911*
Fax: *+33 1 55873912*

143/147 boulevard Anatole France - F-93285 Saint-Denis Cedex - Tél.: +33(0)1 55 87 30 00 - www.ansm.sante.fr